4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
We observed excellent tolerability and clinical activity in these high anti-VEGF need patients that we believe support a differentiated profile.
- We observed excellent tolerability and clinical activity in these high anti-VEGF need patients that we believe support a differentiated profile.
- R&D Expenses: Research and development expenses were $22.4 million for the quarter ended March 31, 2023 as compared to $19.4 million for the first quarter of 2022.
- G&A Expenses: General and administrative expenses were $8.0 million for the quarter ended March 31, 2023 as compared to $8.2 million for the first quarter of 2022.
- Net Loss: Net loss was $28.7 million for the quarter ended March 31, 2023, as compared to $26.3 million for the first quarter of 2022.